Psychopharmacology

A panel of expert psychiatrists define deprescribing as ongoing medication review, guiding safer, personalized psychopharmacology amid polypharmacy, misdiagnosis, and fragmented care.

How do you pick an LAI antipsychotic? Molecule first, delivery system second, Jacob Hanaie, PharmD, shared at SoCal Psychiatry.

At the Southern California Psychiatry Conference, Jason Kellogg, MD, shares insights into the evolution of the MDD pipeline, with an eye on rapid-acting novel mechanisms.

Open-label phase 2 trial tests IV Briumvi alongside antipsychotics for treatment-resistant schizophrenia, targeting B-cell depletion to improve symptoms and assess safety.

Psychiatrists debunk 10 common antidepressant myths—placebo claims, addiction fears, suicide risk, overuse, and withdrawal—offering evidence-based guidance.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.

Learn how CYP450 genetics, phase 2 metabolism, and drug interactions shape psychiatric dosing—what’s actionable now and what’s next in PPGx.

Phase 2 IRIS finds ML-004 misses social communication goals in autism, but notably reduces irritability in teens.

FDA issues CRL for cytisinicline, citing manufacturing issues.

REFRESH data show once-nightly sodium oxybate real-world outcomes.

REFRESH real-world study follows once-nightly sodium oxybate in narcolepsy.

Explore the intersections of bipolar disorder with clinical trials and AI.

Caplyta boosts antidepressants in MDD, showing 2–4 week response with minimal weight, metabolic, and EPS risks.

Delphi panel reveals how NPs and PAs can talk about long-acting injectables earlier in schizophrenia, boosting adherence and cutting relapse.

Once-nightly regular-release lithium cuts kidney risk, maintains bipolar control, improves adherence, and guides safer serum levels.

Alixorexton boosts wakefulness in type 1 narcolepsy, shows cognitive and fatigue gains, and hints at ADHD and neurodegenerative uses.

Why psychiatrists must talk about sex: sexual dysfunction can exacerbate comorbid psychiatric disorders and contribute to medication nonadherence.

How AI can aid everyday psychiatry—TRD prediction, suicide risk, and smartphone phenotyping—plus why data quality and workflow still block adoption.

Phase 2 depression trial shows ALTO-203 boosts attention, EEG theta-beta ratio and alertness, pointing to biomarker-guided dosing and precision psychiatry.

Explore 2026’s fast-moving psych med pipeline: new Alzheimer agitation option, potential novel ADHD therapy, and promising psilocybin for depression.

Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.

Expert analysis compares adjunctive atypical antipsychotics for MDD, highlighting lumatperone’s larger effect and minimal weight gain or akathisia.

FDA issues CRL for CTx-1301 in ADHD.

Weighing the risks and benefits of stimulants to treat ADHD.